[
    [
        {
            "time": "2018-10-15",
            "original_text": "AbbVie Stock Is Making A Comeback On Inflammatory Drugs — Is It A Buy Now?",
            "features": {
                "keywords": [
                    "AbbVie",
                    "comeback",
                    "inflammatory drugs"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie Stock Is Making A Comeback On Inflammatory Drugs — Is It A Buy Now?",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-10-16",
            "original_text": "Recovery in Drugs Sales to Aid AbbVie's (ABBV) Q3 Earnings",
            "features": {
                "keywords": [
                    "recovery",
                    "drugs sales",
                    "Q3 earnings"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Recovery in Drugs Sales to Aid AbbVie's (ABBV) Q3 Earnings",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recenity": 9
            }
        },
        {
            "time": "2018-10-17",
            "original_text": "Healthcare ETFs in Focus as Q3 Earnings Unfold",
            "features": {
                "keywords": [
                    "healthcare ETFs",
                    "Q3 earnings"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Healthcare ETFs in Focus as Q3 Earnings Unfold",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-18",
            "original_text": "AbbVie Takes Another Step Toward Its Post-Humira Future",
            "features": {
                "keywords": [
                    "AbbVie",
                    "post-Humira future"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie Takes Another Step Toward Its Post-Humira Future",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-10-19",
            "original_text": "3 Stocks You Can Still Buy on Sale in a Ridiculously Expensive Market",
            "features": {
                "keywords": [
                    "stocks",
                    "buy on sale",
                    "expensive market"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "3 Stocks You Can Still Buy on Sale in a Ridiculously Expensive Market",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        }
    ]
]